ACT supports multidisciplinary, collaborative academic research focused on restoring the microbiome with one goal in mind...cures! Our research projects and collaborations are rapidly expanding and spread across multiple health conditions. Read more about our academic collaborators and current research projects below.
A Phase 2, double-blind, placebo-controlled trial assessing the impact of Microbiota Transfer Therapy in patients with Pitt-Hopkins Disease, a genetic disease associated with a severe form of Autism. Trial results are expected by the end of the year. More details on the study are available here. Another trial is in development with a next-generation microbiota therapeutic to allow more patients access who are unable to swallow the standard microbiota therapeutic capsules.
Placebo controlled trials are studying the impact of microbial restoration in patients with end stage liver disease and cirrhosis who can experience confusion due to high ammonia and inflammation connected to changes in the gut microbiome. Additional information on this clinical trial is available here. Read more about the impact of microbial composition in liver disease and cirrhosis here.
A randomized, double-blind, placebo controlled trial investigating the impact of microbial restoration on patients being treated with intensive chemotherapy for acute leukemia. Study details are available here.
A placebo-controlled trial at the University of Minnesota investigating the role of bacteria linked to hydrogen sulfide gas and inflammation in Ulcerative Colitis. This study is nearing the end of its recruitment goal. Visit their site to learn more about the study and enrollment qualifications. Hear more from the principal investigator, Dr. Byron Vaughn and in the publication.
This phase 1 single blinded, placebo-controlled trial is currently recruiting patients. More trial information and eligibility criteria are available here.
This placebo-controlled trial has reached recruitment goals and should have results available by the end of the year. Hear more about the impact of microbial restoration on Graft Versus Host Disease and non-cancer related mortality after bone marrow transplantation from Dr. Shernan Holtan at the University of Minnesota here and from Dr. Armin Rashidi here.
This phase 2 clinical trial is investigating the efficacy of Fecal Microbiota Transplant in treating recurrent C. difficile infections. More information on the clinical trial is available here.
A phase 2 double blind, double placebo-controlled clinical trial studying the impact of Fecal Microbiota Transplant in treating recurrent C. difficile Infections in solid organ transplant recipients. Trial details are available here.
Clinicians and providers in this collaborative trial are actively treating patients with recurrent C. difficile infections through Intestinal Microbiota Transplants and maintaining a single registry evaluating clinical results.
This phase 1, open label study has begun recruitment. More information is available here. Read more from the investigators in their publication (link to abstract only, access available upon request to the investigators or a journal subscription).
A Phase 2, double-blind, placebo-controlled study is underway at Arizona State University utilizing Microbiota Transplant Therapy with pediatric and adult patients. More information regarding the current trial is available here.
Click below to view information on previous trials.
Details on this Phase II, double blind, placebo controlled trial are available here.
Investigators are researching the impact of Microbiota Transfer Therapy on Autism and gastrointestinal symptoms in patients with Autism. A phase 1 clinical trial found Autism symptoms reduced nearly 50% two years after microbiota therapy. Read more about the initial trial.
Additional information about the Autism Research Program at Arizona State University is available here.
ASU Researchers Dr. James Adams& Dr. Rosa Krajmalnik-Brown share results from their research.
Hear from patients enrolled in the trial and here.
Researchers investigated the impact of altering the microbial composition on metabolizing sugar in pre-diabetic patients. Participants received an Intestinal Microbiota Transplant from screened, lean donors. Additional clinical trial information is available here.